Baili Tianheng announced that the first phase III randomized controlled clinical trial of locally advanced or metastatic biliary tract cancer that failed to be treated with platinum-containing chemotherapy, expressed in HER2, an innovative biopharmaceutical developed independently by the company, has completed enrollment. The drug has the best potential in its class. Currently, 19 clinical trials are being carried out at home and abroad, covering multiple indications such as first-line and second-line HER2-positive breast cancer, HER2-positive post-operative adjuvant treatment for HER2-positive breast cancer, HER2-positive breast cancer, HER2-positive gastric or gastroesophageal adenocarcinoma, HER2 mutated non-squamous non-small cell lung cancer, and HER2 positive platinum-containing chemotherapy failure, as well as lung cancer, gastrointestinal tumors, urinary system tumors, and gynecological tumors.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.